CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Monopar Therapeutics Inc. - MNPR CFD

    -
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread -
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.024874%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.002651%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* N/A
    Open* N/A
    1-Year Change* N/A
    Day's Range* N/A
    52 wk Range 1.30-4.88
    Average Volume (10 days) 102.83K
    Average Volume (3 months) 754.41K
    Market Cap 18.34M
    P/E Ratio -100.00K
    Shares Outstanding 13.19M
    Revenue N/A
    EPS -0.83
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date May 10, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low

    Monopar Therapeutics Inc. Events

    Time (UTC) Country Event
    Monday, April 3, 2023

    Time (UTC)

    17:00

    Country

    US

    Event

    Monopar Therapeutics Inc at Jefferies Radiopharma Innovation Summit
    Monopar Therapeutics Inc at Jefferies Radiopharma Innovation Summit

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Revenue 0 0
    Total Operating Expense 10.5369 9.12725 6.50888 4.32376 3.33115
    Selling/General/Admin. Expenses, Total 2.94528 2.63404 2.44368 2.35524 1.55669
    Research & Development 7.5916 6.49321 4.0652 1.96852 1.77445
    Operating Income -10.5369 -9.12725 -6.50888 -4.32376 -3.33115
    Interest Income (Expense), Net Non-Operating 0.02124 0.02402 0.0819 0.09889 0.10322
    Net Income Before Taxes -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Net Income After Taxes -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Net Income Before Extra. Items -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Net Income -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Income Available to Common Excl. Extra. Items -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Income Available to Common Incl. Extra. Items -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Diluted Net Income -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Diluted Weighted Average Shares 12.7182 12.4722 10.9583 10.421 10.421
    Diluted EPS Excluding Extraordinary Items -0.82682 -0.72988 -0.57533 -0.40542 -0.30975
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -0.82682 -0.72988 -0.57533 -0.40542 -0.30975
    Other, Net 0 0.1224
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total revenue 0 0 0 0 0
    Total Operating Expense 2.909 2.40735 2.76335 2.45719 2.68112
    Selling/General/Admin. Expenses, Total 0.80874 0.67512 0.68488 0.77925 0.69844
    Research & Development 2.10297 1.73223 2.07847 1.67793 1.98268
    Operating Income -2.909 -2.40735 -2.76335 -2.45719 -2.68112
    Interest Income (Expense), Net Non-Operating 0.01266 0.0077 0.00042 0.00046 0.00053
    Net Income Before Taxes -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Net Income After Taxes -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Net Income Before Extra. Items -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Net Income -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Income Available to Common Excl. Extra. Items -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Income Available to Common Incl. Extra. Items -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Diluted Net Income -2.89634 -2.39965 -2.76293 -2.45672 -2.68059
    Diluted Weighted Average Shares 12.8795 12.7547 12.6324 12.6044 12.5919
    Diluted EPS Excluding Extraordinary Items -0.22488 -0.18814 -0.21872 -0.19491 -0.21288
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -0.22488 -0.18814 -0.21872 -0.19491 -0.21288
    Other Operating Expenses, Total -0.00271
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 20.5216 16.7998 13.2296 7.25222 9.13124
    Cash and Short Term Investments 20.3039 16.7371 13.2139 6.89277 8.98189
    Cash & Equivalents 20.3039 16.7371 13.2139 6.89277 8.98189
    Other Current Assets, Total 0.21775 0.06269 0.01571 0.35945 0.14934
    Total Assets 20.5216 16.8687 13.352 7.31796 9.93127
    Other Long Term Assets, Total 0 0.06886 0.12238 0.06573 0.80003
    Total Current Liabilities 1.58054 1.17667 0.72417 0.39955 0.31187
    Payable/Accrued 1.58054 1.17667 0.72417 0.39955 0.31187
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 1.58054 1.17667 0.72417 0.39955 0.31187
    Total Long Term Debt 0 0 0 0 0
    Total Equity 18.9411 15.692 12.6279 6.9184 9.6194
    Preferred Stock - Non Redeemable, Net
    Common Stock 0.0126 0.01145 0.01059 0.00929 0.00929
    Additional Paid-In Capital 60.22 47.8736 38.5088 28.5672 28.0379
    Other Equity, Total -0.00316 -0.00787 -0.01097 -0.0024 -18.4278
    Total Liabilities & Shareholders’ Equity 20.5216 16.8687 13.352 7.31796 9.93127
    Total Common Shares Outstanding 12.5981 11.4535 10.6215 10.421 10.421
    Retained Earnings (Accumulated Deficit) -41.2884 -32.1852 -25.8806 -21.6557
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 18.0127 20.5216 22.4484 24.3884 25.8377
    Cash and Short Term Investments 17.819 20.3039 22.3416 24.2929 25.7231
    Cash & Equivalents 17.819 20.3039 22.3416 24.2929 25.7231
    Other Current Assets, Total 0.19364 0.21775 0.1068 0.09556 0.11457
    Total Assets 18.0664 20.5216 22.5172 24.4573 25.9065
    Other Long Term Assets, Total 0 0.06886 0.06886 0.06886
    Total Current Liabilities 1.07412 1.58054 1.23994 1.10364 0.80627
    Payable/Accrued 1.04815 1.58054 1.23994 1.10364 0.80627
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 1.09946 1.58054 1.23994 1.10364 0.80627
    Total Long Term Debt 0 0 0 0 0
    Total Equity 16.9669 18.9411 21.2773 23.3536 25.1003
    Common Stock 0.01262 0.0126 0.01259 0.01258 0.01257
    Additional Paid-In Capital 60.7031 60.22 59.8776 59.4955 59.162
    Retained Earnings (Accumulated Deficit) -43.7451 -41.2884 -38.6078 -36.1493 -34.0692
    Other Equity, Total -0.00374 -0.00316 -0.00515 -0.00516 -0.0051
    Total Liabilities & Shareholders’ Equity 18.0664 20.5216 22.5172 24.4573 25.9065
    Total Common Shares Outstanding 12.6206 12.5981 12.5906 12.5827 12.5699
    Property/Plant/Equipment, Total - Net 0.05369
    Accrued Expenses 0.02598
    Other Liabilities, Total 0.02534
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -10.5156 -9.10322 -6.30457 -4.22487 -3.22793
    Cash From Operating Activities -7.22856 -7.3174 -4.66227 -3.01768 -2.68049
    Non-Cash Items 1.64126 1.46805 1.19849 1.01117 0.52933
    Changes in Working Capital 1.64582 0.31777 0.44381 0.19602 0.01811
    Cash From Financing Activities 0.03287 10.8795 8.18212 9.34741 -0.20627
    Financing Cash Flow Items -0.07663 -0.06325 -0.11557 -0.98481 -0.20627
    Issuance (Retirement) of Stock, Net 0.10951 10.9428 8.17529 10.3322 0
    Net Change in Cash -12.1177 3.56676 3.52318 6.32116 -2.88915
    Foreign Exchange Effects -0.00348 0.00462 0.00333 -0.00857 -0.0024
    Cash Taxes Paid 0 -0.0111
    Issuance (Retirement) of Debt, Net 0.1224
    Cash From Investing Activities -4.91851
    Other Investing Cash Flow Items, Total -4.91851
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Net income/Starting Line -10.5156 -7.6193 -5.21965 -2.45672 -9.10322
    Cash From Operating Activities -7.22856 -5.92675 -3.77828 -2.4675 -7.3174
    Non-Cash Items 1.64126 1.24785 0.85711 0.49981 1.46805
    Changes in Working Capital 1.64582 0.4447 0.58427 -0.51059 0.31777
    Cash From Financing Activities 0.03287 -0.10586 -0.08213 -0.01667 10.8795
    Financing Cash Flow Items -0.07663 -0.10603 -0.08217 -0.01667 -0.06325
    Issuance (Retirement) of Stock, Net 0.10951 0.00017 0.00004 0 10.9428
    Foreign Exchange Effects -0.00348 0.04521 0.0201 -0.00066 0.00462
    Net Change in Cash -12.1177 -5.98741 -3.8403 -2.48483 3.56676
    Issuance (Retirement) of Debt, Net
    Cash From Investing Activities -4.91851
    Other Investing Cash Flow Items, Total -4.91851
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Tacticgem LLC Corporation 31.1621 4111273 0 2022-04-15 LOW
    Gem Pharmaceuticals LLC Corporation 23.1589 3055394 0 2022-04-15 LOW
    Hendricks (Diane) Individual Investor 3.553 468750 0 2022-04-15 LOW
    Brown Michael J Individual Investor 1.711 225730 2859 2022-12-31 LOW
    Tactic Pharma LLC Corporation 1.2633 166667 0 2022-04-15 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 0.7578 99976 97 2022-12-31 LOW
    Robinson (Chandler D) Individual Investor 0.5816 76730 4396 2023-01-01 LOW
    Starr (Christopher M) Individual Investor 0.4937 65130 2859 2022-12-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.3175 41892 2721 2022-12-31 LOW
    Cittadine (Andrew) Individual Investor 0.2038 26894 2656 2022-12-31 HIGH
    Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1735 22884 -293 2022-12-31 LOW
    Mazar (Andrew Paul) Individual Investor 0.1677 22125 0 2022-04-15 LOW
    Klausner (Arthur J) Individual Investor 0.1571 20730 2859 2022-12-31 LOW
    Tsuchimoto (Kim R) Individual Investor 0.1403 18507 728 2023-01-01 MED
    Anderson (Raymond William) Individual Investor 0.1268 16730 2859 2022-12-31 MED
    Northern Trust Global Investments Investment Advisor 0.1 13197 0 2022-12-31 LOW
    Morgan Stanley Smith Barney LLC Investment Advisor 0.0303 4000 0 2022-12-31 LOW
    UBS Financial Services, Inc. Investment Advisor 0.0239 3154 -2245 2022-12-31 LOW
    Tower Research Capital LLC Hedge Fund 0.0215 2831 -300 2022-12-31 HIGH
    Paragon Wealth Strategies, LLC Investment Advisor 0.0004 58 0 2022-12-31 HIGH

    Start a global, multi-asset portfolio with an award-winning platform

    Trade now Desktop

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Monopar Therapeutics Inc. Company profile

    About Monopar Therapeutics Inc

    Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.

    Financial summary

    BRIEF: For the nine months ended 30 September 2021, Monopar Therapeutics Inc revenues was not reported. Net loss increased 54% to $6.4M. Higher net loss reflects Interest income decrease of 67% to $23K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.39 to -$0.52.

    Industry: Biotechnology & Medical Research (NEC)

    1000 Skokie Blvd Ste 350
    WILMETTE
    ILLINOIS 60091-1146
    US

    Income Statement

    • Annual
    • Quarterly

    News

    A file photo shows a part of a stack of 500 Canadian gold coins, worth $1 million USD according to Sprott Money, is displayed at the precious metals dealer's booth at the Prospectors and Developers Association of Canada (PDAC) annual conference in Toronto

    PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise

    Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.

    09:37, 31 March 2023
    People use DBS automated teller machines (ATMs) in Singapore March 31, 2022.

    Singapore's DBS has seen inflows in SVB aftermath, CEO says

    DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.

    09:24, 31 March 2023
    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., March 29, 2023.

    US STOCKS-Futures muted as investors await key inflation data

    U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.

    09:16, 31 March 2023
    A file photo of the logo of Australian energy company Origin pictured in Melbourne, Australia, July 3, 2016

    Asia M&As drop to decade low as tumultuous backdrop deters dealmaking

    Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.

    09:14, 31 March 2023
    A file photo of a worker shoveling coal in a supply truck at a yard on the outskirts of Ahmedabad, India, October 25, 2018.

    Coal India surpasses annual output target for first time in 17 years

    Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.

    09:13, 31 March 2023
    A file photo of bull and bear symbols in front of the German stock exchange in Frankfurt, Germany, February 12, 2019.

    Global IPOs marred by banks and recession enjoy few bright spots

    A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.

    09:06, 31 March 2023
    A file photo of Unicredit Bank logo seen in this illustration taken March 12, 2023.

    UniCredit shareholders gather to vote on CEO's new pay scheme

    Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.

    09:04, 31 March 2023

    People also watch

    Oil - Crude

    75.76 Price
    +1.830% 1D Chg, %
    Long position overnight fee -0.0156%
    Short position overnight fee -0.0063%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    Natural Gas

    2.20 Price
    +3.540% 1D Chg, %
    Long position overnight fee -0.4092%
    Short position overnight fee 0.3873%
    Overnight fee time 21:00 (UTC)
    Spread 0.005

    Gold

    1,969.66 Price
    -0.550% 1D Chg, %
    Long position overnight fee -0.0185%
    Short position overnight fee 0.0102%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    US100

    13,186.80 Price
    +1.680% 1D Chg, %
    Long position overnight fee -0.0249%
    Short position overnight fee 0.0027%
    Overnight fee time 21:00 (UTC)
    Spread 3.0

    Still looking for a broker you can trust?

    Join the 500.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading